SELLAS Life Sciences Group, Inc. Common Stock (SLS)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 13
- Market Cap
- $2.4B
About SELLAS Life Sciences Group, Inc. Common Stock
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
SentiSense also tracks daily options readings for SELLAS Life Sciences Group, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
SELLAS Life Sciences Group, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.